Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Serenus Biotherapeutics

Request full access

Privately held specialty biopharmaceutical company

San Francisco, United StatesFounded 2013Biotech & Life Sciences

About Serenus Biotherapeutics

Founded in 2014 by Dr. Menghis Bairu, Serenus Biotherapeutics, Inc. was a specialty biopharmaceutical company with a strategic focus on the African continent. The company was established to bridge the divide between the world's leading pharmaceutical markets and the growing demand for therapies in emerging African nations. Dr. Bairu, who served as CEO and President, brought extensive experience from a multi-decade career in the international biotechnology and pharmaceutical sectors, including roles at Genentech and Elan Corporation. His personal journey, from fleeing war-torn Eritrea to becoming a successful physician and biotech executive, fueled the company's mission to address unmet medical needs in underserved regions.

Serenus Biotherapeutics operated by in-licensing, registering, and commercializing late-stage drugs and medical devices that were already approved in markets like the United States, Europe, and Japan. The business model centered on securing commercialization rights for these products to treat diseases with high prevalence in Sub-Saharan Africa, such as hypertension and other chronic, non-communicable diseases. A key part of its strategy involved creating partnerships with global pharmaceutical companies to introduce their products to the African market. For instance, the company entered an agreement with Hanmi Pharmaceutical to supply 'Amosartan', a combination therapy for hypertension. This approach aimed to capitalize on the rising demand for advanced medications driven by economic growth and urbanization in Africa.

The company's financing was significantly bolstered in March 2015 when it secured an investment of up to $43 million from Malin Corporation plc, an Ireland-based global life sciences company. The deal involved an initial $18 million for a 41% stake, with provisions for Malin to increase its stake later. These funds were earmarked for operational development, building out a late-stage clinical development pipeline, and establishing a comprehensive supply chain network across its target markets. Despite its ambitions and securing significant venture capital, PitchBook data indicates the company ceased operations as of December 1, 2022.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Mar 2015 $43M $172M Malin Corporation —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Serenus Biotherapeutics website traffic

Latest recorded traffic for Serenus Biotherapeutics is 230 monthly website visits.

Latest monthly visits230
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Serenus Biotherapeutics in the San Francisco ecosystem

Live from Dealroom

The Serenus Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Malin Corporation
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Serenus Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Serenus Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.